No Data
No Data
Leadman (300289.SZ): There are currently no plans to directly invest in or acquire Yixi Biotech
On May 13, Ge Longhui | Leadman (300289.SZ) said on the investor interactive platform that the company's products in the field of immunotesting mainly include chemiluminescence kits and related diagnostic instruments. The company currently has no plans to directly invest in or acquire Yixi Biotech.
Leadman (300289.SZ) 2023 equity distribution: 0.1 yuan for every 10 shares, shares registered on May 16
Leadman (300289.SZ) issued an announcement. The company's 2023 equity distribution plan is: Based on the company's existing...
Leadman (300289.SZ): Enzyme products are currently mainly used in the development and production of biochemical diagnostic reagents
Gelonghui, May 8 | Leadman (300289.SZ) said on the investor interactive platform that the company's enzyme products are currently mainly used in the development and production of biochemical diagnostic reagents.
Leadman (300289.SZ): Not involved in the field of synthetic biology
Glonghui, May 6 | Leadman (300289.SZ) said on the investor interactive platform that the company is currently focusing on the in vitro diagnosis industry and has not yet involved the field of synthetic biology.
Leadman (300289.SZ): Net loss of 2.751 million yuan in the first quarter
Gelonghui, April 25 | Leadman (300289.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 94.6241 million yuan, down 12.51% year on year; net profit attributable to shareholders of listed companies - 27.51 million yuan, year-on-year profit and loss; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 4.8794 million yuan; basic earnings per share - 0.0050 yuan.
Leadman (300289.SZ): Currently, e-commerce platforms and cross-border e-commerce platform promotion channels are not involved
Gelonghui, April 8 | Leadman (300289.SZ) said on the investor interactive platform that at this stage, the company promotes products and brands through various forms such as online marketing, public account tweets, academic marketing, thematic salons, expert satellite meetings, product promotion conferences, etc., and is actively building celebrity classrooms and scientific research courses as academic leading platforms to increase the recognition and satisfaction of end users with the company's products through academic brand influence, so as to strengthen academic construction of benchmark hospitals and in-depth cooperation with KOL experts. Currently, e-commerce platforms are not involved. Promotion channels with cross-border e-commerce platforms
No Data